title: Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C.
abstract: OBJECTIVE
  The current standard for the determination of sustained virologic response in patients treated for hepatitis C is undetectable hepatitis C virus (HCV) RNA 24 weeks following the completion of therapy. Sensitive molecular tests may permit earlier determination of sustained virologic response following the completion of therapy in end-of-treatment responders.
  
  
  METHODS
  We examined this possibility in 1441 patients, who received 48 weeks of treatment with either standard or pegylated interferon alpha-2a. HCV RNA was determined by polymerase chain reaction assay (Amplicor HCV Monitor vs. 2.0) at baseline and monitored at 4-week intervals throughout the treatment and 24-week post-treatment follow-up periods.
  
  
  RESULTS
  End-of-treatment and sustained response were achieved in 624 and 342 patients, respectively. For all treatments, relapse was most frequent at weeks 52 and 56 and became rare following week 60. Only six patients out of 348 patients (2%) became HCV RNA positive between weeks 60 and 72. Analysis of baseline characteristics failed to identify a specific set of parameters associated with early relapse.
  
  
  CONCLUSIONS
  This finding suggests that determination of HCV RNA levels at 12 weeks of follow-up may be sufficient for making decisions related to the management of most patients treated with standard or pegylated interferon alpha.
authors.affiliation: Klinik für Innere Medizin II, Universitätskliniken des Saarlandes, 66421 Homburg/Saar, Germany. zeuzem@uniklinik-saarland.de
authors.forename: Stefan
authors.initials: S
authors.lastname: Zeuzem
authors.forename: E Jenny
authors.initials: EJ
authors.lastname: Heathcote
authors.forename: Mitchell L
authors.initials: ML
authors.lastname: Shiffman
authors.forename: Teresa L
authors.initials: TL
authors.lastname: Wright
authors.forename: Vincent G
authors.initials: VG
authors.lastname: Bain
authors.forename: Morris
authors.initials: M
authors.lastname: Sherman
authors.forename: S Victor
authors.initials: SV
authors.lastname: Feinman
authors.forename: Michael W
authors.initials: MW
authors.lastname: Fried
authors.forename: Jens
authors.initials: J
authors.lastname: Rasenack
authors.forename: Christoph
authors.initials: C
authors.lastname: Sarrazin
authors.forename: Donald M
authors.initials: DM
authors.lastname: Jensen
authors.forename: Amy
authors.initials: A
authors.lastname: Lin
authors.forename: Joseph H
authors.initials: JH
authors.lastname: Hoffman
authors.forename: Farhad
authors.initials: F
authors.lastname: Sedarati
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D012367:RNA, Viral / Q000032:analysis; D011994:Recombinant Proteins; D012008:Recurrence
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a